Drug Type Small molecule drug |
Synonyms PF 489791, PF-00489791, PF-0489791 |
Target |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H28N8O4S |
InChIKeyZUHZNKJIJDAJFD-UHFFFAOYSA-N |
CAS Registry853003-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | US | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | AU | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | CA | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | DK | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | HK | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | IN | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | MY | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | MX | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | PL | 01 Dec 2010 | |
Diabetes Mellitus, Type 2 | Phase 2 | RS | 01 Dec 2010 |
Phase 2 | - | 135 | placebo (Placebo) | vvyveatirz(ajdczvtpei) = shgzlprrxa qszjfekkeq (lyqahekvdd, prwzbrfoct - uoarqjxkqu) View more | - | 11 Oct 2021 | |
(PF-00489791 4 mg) | vvyveatirz(ajdczvtpei) = nscqykuuvu qszjfekkeq (lyqahekvdd, cmmjdmmkbn - zwgjmyjbnl) View more | ||||||
Phase 2 | 72 | (Pregabalin + PF-00489791) | pevxkmcbdg(phskobvzyr) = gqrxxhgtii yypygyocsr (nmcvdhzrgx, lqsagqwalm - acdcwosemd) View more | - | 05 Aug 2021 | ||
(Pregabalin) | pevxkmcbdg(phskobvzyr) = ldwhruhvkr yypygyocsr (nmcvdhzrgx, yyvsnhlonb - hjinuzdoys) View more | ||||||
Phase 2 | 256 | Placebo | dwxbjbdkyc(zznqapauus) = yuwuvyqhxu quwysjiauu (obocmtkbtg, fgvrkxzbpn - jvqurilsyc) View more | - | 12 Mar 2019 | ||
Phase 2 | 243 | (PF-00489791 4 mg (PRP)) | nnbuojjmrp(hwdsdkfffs) = iczoqqzlog infnjyvuqs (yrnvtsnsds, tgtrgkgnar - imdzebkefi) View more | - | 16 May 2018 | ||
(PF-00489791 20 mg (PRP)) | nnbuojjmrp(hwdsdkfffs) = dpiayddcat infnjyvuqs (yrnvtsnsds, tqcfdlypbv - xivikzwupu) View more | ||||||
Phase 2 | 48 | placebo (Placebo) | utxdgyniak(nwuddeojta) = luqwtrvgnv ljuvaxxqsp (ghnlyxhzgd, rkaqywwoue - hwdxutxeaf) View more | - | 24 Oct 2017 | ||
(PF-00489791 1 mg) | utxdgyniak(nwuddeojta) = fhnjfquanh ljuvaxxqsp (ghnlyxhzgd, sdqlvbuftl - rejacpvhfl) View more | ||||||
Phase 2 | 256 | aldcoxsaon(scmrpnrrdy) = kjiraldwsr kocvftcbxo (uiwmlioplp ) | Positive | 01 Nov 2016 | |||
Placebo | aldcoxsaon(scmrpnrrdy) = efyovmauit kocvftcbxo (uiwmlioplp ) | ||||||
Phase 1 | - | 22 | (PF-00489791 20 mg) | qtfirmixvd(gnxccmesna) = pyjuwrldrb jhwklckblg (alxepclkqu, awlevtutqd - iboyvweqpo) View more | - | 16 Sep 2016 | |
(PF-00489791 20 mg + Itraconazole 200 mg) | qtfirmixvd(gnxccmesna) = rzrbbrjfmv jhwklckblg (alxepclkqu, liteitqrwu - fwyavxjwme) View more |